close

Products

1 140 141 142 143
Number of results: 2851
Date Compound Product name Company Disease Action mechanism Type of Information
2011-12-19 azilsartan medoxomil Edarbi® (Ipreziv®) Takeda Pharmaceutical (Japan)

essential hypertension in adults

azilsartan medoxomil is an angiotensin II receptor blocker. Granting of a Market Authorisation in the EU
2011-12-19 fixed dose combination of emtricitabine, rilpivirine and tenofovir disoproxil Eviplera® Gilead Sciences (USA)

HIV-1 infection

All three substances act by inhibition of HIV-1 reverse transcriptase, an enzyme needed for replication of the virus; rilpivirine hydrochloride… Granting of a Market Authorisation in the EU
2011-12-19 nasally administered four-strain live attenuated influenza vaccine Fluenz® Tetra/FluMist® Quadrivalent AstraZeneca (UK)

prevention of seasonal influenza in eligible children and adolescents 24 months to 17 years of age

Fluenz Tetra® is formulated to contain four live attenuated influenza virus strains that are weakened so as to not cause… Granting of a Market Authorisation in the EU
2011-12-18 HER2 CISH pharmDx® Kit Dako (Denmark)

assessment of breast cancer patients for whom treatment with Herceptin® is being considered

HER2 CISH pharmDx® Kit is a dual color chromogenic assay designed to quantitatively determine HER2 gene amplifications in breast cancer… Granting of a Market Authorisation in the US
2011-11-24 Combination of saxagliptin and metformin Komboglyze® BMS (USA) AstraZeneca (UK)

type 2 diabetes

in combination with insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type 2 diabetes mellitus when insulin and metformin alone do not provide adequate glycaemic control

Komboglyze® combines two glucose-lowering agents with complementary mechanisms of action. Granting of a Market Authorisation in the EU
2011-10-12 epoetin beta pegol Mircera® Chugai (Japan) Roche (Switzerland) renal anemia long-acting erythropoiesis stimulating agent  Granting of a Market Authorisation in Japan
2011-09-27 dinaciclib dinaciclib Merck&Co (USA)

chronic lymphocytic leukemia

kinase inhibitor. Dinaciclib blocks the action of cyclin-dependent kinases (CDK), which are involved in regulating the cell cycle.  In order… Granting of the orphan status in the US
2011-09-21 cardiotrophin-1 cardiotrophin-1 Digna Biotech (Spain)

acute liver failure

protein. Cardiotrophin-1 (CT-1) is a member of the interleukin (IL) 6 family of cytokines. The effects of CT-1 are documented… Granting of the orphan status in the US
2011-07-18 boceprevir Victrelis® Merck&Co (USA)

chronic hepatitis-C genotype-1 infection

Boceprevir is the first of a new class of medicines for the treatment of chronic hepatitis that directly inhibit the… Granting of a Market Authorisation in the EU
2011-06-24 human embryonic stem-cell-derived retinal pigment epithelial cells human embryonic stem-cell-derived retinal pigment epithelial cells TMC Pharma Services (UK)

Stargardt’s disease

cell therapy. This medicine is made up of retinal pigment epithelial cells. It is expected to be injected directly into… Granting of a patent
2011-06-21 human dermal fibroblasts cultured on a bioresorbable polyglactin mesh human dermal fibroblasts cultured on a bioresorbable polyglactin mesh TMC Pharma Services (UK)

epidermolysis bullosa

The medicine is made up of fibroblasts that have been grown in the laboratory to be used as a skin… Granting of the orphan status in the EU
2011-05-06 everolimus Afinitor® Novartis (Switzerland) advanced neuroendocrine tumors (NET) of pancreatic origin mTOR inhibitor. Everolimus is a selective mTOR (mammalian target of rapamycin) inhibitor. mTOR is a key serine-threonine kinase, the activity… Granting of a Market Authorisation in the US
2011-02-07 MOR103 MOR103 Morphosys (Germany) monoclonal antibody. MOR103 is a human monoclonal antibody to GM-CSF (granulocyte macrophage-colony stimulating factor). Granting of a patent
2010-10-01 16-base single-stranded peptide nucleic acid oligonucleotide linked to a 7-amino acid peptide 16-base single-stranded peptide nucleic acid oligonucleotide linked to a 7-amino acid peptide Biogenera (Italy)

medulloblastoma

antisens oligoucleotide.  16-Base single-stranded peptide nucleic acid oligonucleotide linked to a 7-amino acid peptide has been designed to block the gene coding… Granting of the orphan status in the EU
2007-11-29 human recombinant interferon-beta 1a Traumakine® - FP-1201 Faron Pharmaceuticals (Finland)

acute lung injury (ALI) acute respiratory distress syndrome (ARDS)

protein. FP-1201/Traumakine® is a human recombinant interferon-beta 1a. In acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), the predominant patho-physiological result… Granting of a patent
0000-00-00 rasagiline mesylate rasagiline mesylate Takeda Pharmaceutical (Japan) Parkinson’s disease Rasagiline is a monoamine oxidase B (MAO-B) inhibitor. By irreversibly binding to MAO-B, it prevents the breakdown of dopamine in… Submission of an NDA
0000-00-00 eculizumab Soliris® Alexion Europe (Switzerland) myasthenia gravis, refractory generalized myasthenia gravis  in patients who are anti-acetylcholine receptor (AChR) antibody-positive monoclonal antibody. Eculizumab is a recombinant humanized monoclonal IgG2/4 antibody that specifically binds to the complement protein C5, inhibiting its… Granting of a Market Authorisation in Japan
0000-00-00 Plant acquisition
0000-00-00 Compound: Product name: sadasd dsadasdasd asdasdasdas Plant acquisition
0000-00-00 hj hjgh j vhv j Validation of a production plant